Clinical Trial Update: Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety and tolerability of MSK-DA01 cell therapy in advanced Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• MSK-DA01 Cell Therapy

Snippet

Sponsor: BlueRock Therapeutics | Conditions: Advanced Parkinson's Disease | Phase 1 | Status: COMPLETED